Synapse - Benjamin Diamond

Results (27)

Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens

Journal Article

Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
Nature Cancer (2023)

Fulltext@MSK | Save

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma

Journal Article

Maclachlan, K. H.; Rustad, E. H.; Derkach, A.; Zheng-Lin, B.; Yellapantula, V.; Diamond, B.; Hultcrantz, M.; Ziccheddu, B.; Boyle, E. M.; Blaney, P.; more...
Nature Communications (2021)

Fulltext@MSK | Save

Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial

Journal Article

Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
JAMA Oncology (2021)

Fulltext@MSK | Save

Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma

Journal Article

Jonsdottir, G.; Björkholm, M.; Turesson, I.; Hultcrantz, M.; Diamond, B.; Porwit, A.; Landgren, O.; Kristinsson, S. Y.
European Journal of Haematology (2021)

Fulltext@MSK | Save

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial

Journal Article

Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
The Lancet Haematology (2021)

Fulltext@MSK | Save

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone

Research Letter

Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
American Journal of Hematology (2021)

Fulltext@MSK | Save

Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001

Journal Article

Maura, F.; Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V. D.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Minimal residual disease in multiple myeloma: Defining the role of next generation sequencing and flow cytometry in routine diagnostic use

Review

Maclachlan, K. H.; Came, N.; Diamond, B.; Roshal, M.; Ho, C.; Thoren, K.; Mayerhoefer, M. E.; Landgren, O.; Harrison, S.
Pathology (2021)

Fulltext@MSK | Save

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

Journal Article

Oben, B.; Froyen, G.; Maclachlan, K. H.; Leongamornlert, D.; Abascal, F.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Geerdens, E.; Diamond, B. T.; more...
Nature Communications (2021)

Fulltext@MSK | Save

Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity

Review

Diamond, B. T.; Rustad, E.; Maclachlan, K.; Thoren, K.; Ho, C.; Roshal, M.; Ulaner, G. A.; Landgren, C. O.
Blood Reviews (2021)

Fulltext@MSK | Save